Phase 1 to Investigate Safety, Tolerability, PK/PD of J2H-1702 in Healthy Females
Status:
COMPLETED
Trial end date:
2023-02-17
Target enrollment:
Participant gender:
Summary
\- Objectives: Primary objective\_To evaluate the safety and tolerability after single oral administration of the investigational product (IP), J2H-1702 in healthy female subjects. Secondary objective\_To evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) characteristics after single oral administration of the IP, J2H-1702 in healthy female subjects.